Deccan Health Care has accepted the resignation of Parth H Palera from the position of Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) effective June 25, 2026. The executive resigned to pursue better professional opportunities, as confirmed in a regulatory filing submitted to BSE Limited.

Palera ceased to be the KMP authorised for determining the materiality of an event or information and for making disclosures to stock exchanges with effect from the close of business hours on June 25, 2026. The company stated that there is no other material reason for the resignation other than the stated professional opportunity.

The resignation was submitted pursuant to Regulation 30 and Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made by Shikha Das, Company Secretary & Compliance Officer of deccan health care .

Resignation Details

The following table outlines the key particulars of the change in managerial personnel as per the SEBI Listing Regulations:

Deccan Health Care Limited reported a 91.2% increase in net profit to ₹229.05 lakh for the financial year ended March 31, 2026, compared to ₹13.60 lakh in the previous year. Revenue from operations for the year rose 18.7% to ₹8,917.10 lakh from ₹7,513.19 lakh in FY25. The company’s board approved the standalone and consolidated audited financial results for FY26 at a meeting held on May 30, 2026. The results were reviewed by the Audit Committee and subsequently published in newspapers on June 01, 2026, pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance for FY26

The growth in annual profitability was supported by a rise in total income, which reached ₹8,917.97 lakh for the year ended March 31, 2026, up from ₹7,513.76 lakh in the prior year. Total expenses for FY26 increased to ₹8,612.39 lakh from ₹7,346.84 lakh in the previous year. The finance costs for the year surged to ₹36.61 lakh compared to ₹7.39 lakh in FY25.

For the quarter ended March 31, 2026, the company posted a net profit of ₹22.75 lakh, a decline from ₹95.07 lakh in the quarter ended December 31, 2025. Revenue from operations for the quarter stood at ₹2,026.49 lakh, down from ₹2,303.20 lakh in the preceding quarter.

Segment and Capital Structure

The company operates in a single segment focused on the manufacturing of nutraceutical products. Paid-up equity share capital increased to ₹2,474.92 lakh as of March 31, 2026, from ₹2,342.55 lakh in the previous year. During the year, the company issued and allotted 13,23,667 equity shares upon receipt of full consideration for share warrants. Additionally, ₹75.00 lakh received towards initial consideration for 10,00,000 warrants was forfeited due to non-exercise of the conversion option.

Consolidated Results

On a consolidated basis, net profit for FY26 rose to ₹248.76 lakh from ₹12.35 lakh in the previous year. Total consolidated revenue for the year stood at ₹8,190.48 lakh, compared to ₹7,506.36 lakh in FY25. The consolidated results include the financials of subsidiary Beyoungstore Private Limited.

Standalone Financial Results (₹ in Lakhs)